Description and Appraisal of Outcome Measures - Clinical Review Report: Eculizumab (Soliris) - NCBI Bookshelf

Description and Appraisal of Outcome Measures - Clinical Review Report: Eculizumab (Soliris) - NCBI Bookshelf

To describe the following outcome measures and review their measurement properties (validity, reliability, responsiveness to change, and MID): Myasthenia Gravis Activities of Daily Living scale (MG-ADL)Quantitative Myasthenia Gravis (QMG) scoreMyasthenia Gravis Composite (MGC) scoreMyasthenia Gravis Quality of Life 15-item scale (MG-QoL15)Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS)Quality of Life in Neurological Disorders Fatigue Scale (Neuro-QoL Fatigue)European Quality of Life (EuroQol) Health 5-Dimensions (EQ-5D) questionnaire.

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Full article: Quantifying the economic effects of ravulizumab

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Economic Review - Pharmacoeconomic Report: Eculizumab (Soliris

Complement Inhibition in Myasthenia Gravis and Neuromyelitis

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Current Professionals — Clinical Research Certification I Blog - CCRPS

Considerations for the Role of the Pharmacist in Managing Patients

Economic Review - Pharmacoeconomic Report: Eculizumab (Soliris

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris